InterShunt is developing a transcatheter system that excises tissue from the interatrial septum to create a left-to-right atrial shunt, effectively relieving elevated left atrial pressure in heart failure patients. This minimally invasive procedure aims to improve breathing and daily activity levels for over 6 million Americans suffering from heart failure.
Funding
$31.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MIFounders
Product
Problem
Millions of Americans suffer from heart failure, leading to elevated left atrial pressure and causing breathing difficulties and reduced ability to perform daily activities. Current solutions for these patients are limited.
Solution
InterShunt is developing the Percutaneous Atrial Shunt Catheter System (PAS-C), a minimally invasive transcatheter system designed to excise tissue from the interatrial septum. This creates a left-to-right atrial shunt, relieving elevated left atrial pressure and reducing heart failure symptoms. The mechanical system requires no implant or energy. By relieving pressure from the left atrium, the device aims to restore a patient's breathing during normal daily activities.
Target Audience
The primary target audience is heart failure patients experiencing elevated left atrial pressure and the physicians who treat them.
Features
- Transcatheter system for minimally invasive tissue excision in the interatrial septum.
- Creates a left-to-right atrial shunt to relieve elevated left atrial pressure.
- Mechanical system requiring no implant or energy source.